Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease
Mark T. Hamann(James Cook University), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Subagus Wahyuono(Universitas Gadjah Mada), Miguel Medina(Baptist Hospital of Miami), Ana María de Caso Fuertes, Jennifer C. Cook(Universitas Gadjah Mada), Ma. Jose Perez-Puerto(Universitas Gadjah Mada), Ana Castro(Instituto de Química Médica), Balaiah Akula(Universitas Gadjah Mada), Marı́a del Monte-Millán(Hospital General Universitario Gregorio Marañón), Ester Martı́n-Aparicio(Universitas Gadjah Mada), Susana Morales(Universitas Gadjah Mada), D. A. Alonso(Neuron BioPharma (Spain)), Hari Kishore Pennaka(Universitas Gadjah Mada), María Luisa Navarro, Jiangnan Peng(Sinochem Group (China))
Cited by 147
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
(untitled)
|Edinburgh Research Explorer|0|353
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334